Cirtociclib - Blueprint Medicines
Alternative Names: BLU-222Latest Information Update: 28 Apr 2026
At a glance
- Originator Blueprint Medicines
- Class 1 ring heterocyclic compounds; 2 ring heterocyclic compounds; Amines; Antineoplastics; Ethers; Fluorocarbons; Pyrazines; Pyrazoles; Small molecules
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase I/II HER2 negative breast cancer; Solid tumours
- No development reported Cancer; Gynaecological cancer; Ovarian cancer
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for preclinical development in Ovarian-cancer in USA
- 09 Feb 2026 (NCT05252416) - Kdm, intro dev lines added and HE added
- 28 Jan 2026 No recent reports of development identified for preclinical development in Gynaecological-cancer in USA